New drug may keep esophageal cancer from coming back after surgery
NCT ID NCT07332221
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the drug toripalimab, given after surgery, can help prevent esophageal cancer from returning in patients at high risk of recurrence. About 435 adults who have already had chemotherapy and immunotherapy before surgery will either receive toripalimab or be watched closely. The goal is to see if the drug improves survival and delays cancer return.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- Blood test score may flag High-Risk esophageal surgery patients
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can surgery for stomach or esophageal cancer cloud the mind?